Stocks · News reference
Nexalin shares are trading lower. The company reported exploratory ADAS-Cog data from its completed trial of the Gen-2 SYNC DIFS neurostimulation device in in mild Alzheimer’s disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Nexalin Technology, Inc. (NXL)
Filed: 2026-09-02 AccNo: 0001829126-26-009659 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Nexalin Technology shares are trading lower after the company announced a 1-for-30 reverse stock split.